MEDABON

This brand name is authorized in Estonia, Hong Kong SAR China, Romania, South Africa, UK.

Active ingredients

The drug MEDABON contains a combination of these active pharmaceutical ingredients (APIs):

1	Mifepristone UNII 320T6RNW1F - MIFEPRISTONE
	Mifepristone is a synthetic steroid with an antiprogestational action as a result of competition with progesterone at the progesterone receptors.
	Read more about Mifepristone
2	Misoprostol UNII 0E43V0BB57 - MISOPROSTOL
	Misoprostol is an analogue of naturally occurring prostaglandin E1 which promotes peptic ulcer healing and symptomatic relief. Misoprostol protects the gastroduodenal mucosa by inhibiting basal, stimulated and nocturnal acid secretion and by reducing the volume of gastric secretions, the proteolytic activity of the gastric fluid, and increasing bicarbonate and mucus secretion.
	Read more about Misoprostol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MEDABON CO Tablet, Vaginal tablet	MPI, Generic	Health Products Regulatory Authority (ZA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03XB51		G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03X Other sex hormones and modulators of the genital system → G03XB Antiprogestogens
Discover more medicines within G03XB51

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1433056, 1641754
HK	Department of Health Drug Office	64599
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W59313001, W59313002
ZA	Health Products Regulatory Authority	54/21.12/0619